[Novel target therapies used in breast cancer management]

Vopr Onkol. 2011;57(5):592-600.
[Article in Russian]
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Humans
  • Lapatinib
  • Molecular Targeted Therapy / methods*
  • Mutation
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use
  • Quinolines / therapeutic use
  • RANK Ligand / antagonists & inhibitors
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptors, Estrogen / metabolism
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Protein Kinase Inhibitors
  • Quinazolines
  • Quinolines
  • RANK Ligand
  • Receptors, Estrogen
  • TNFSF11 protein, human
  • Lapatinib
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • neratinib
  • pertuzumab
  • Trastuzumab